The Drug Enforcement Administration (DEA) has drafted plans to temporarily classify 7-OH, an opioid-like compound found in kratom, as a Schedule I drug. This move would apply to products containing over a specific threshold of the substance and lasts for two years, with extension potential.

Supporters argue this ban is necessary to address public health concerns, including tolerance, dependence, and addiction. Opponents claim there’s no scientific evidence supporting such drastic measures against 7-OH, which has seen an increase in production and sales over the past few years.

With backing from key government officials, including President Donald Trump, the mainstream kratom industry is celebrating the proposed ban as a victory for public safety. However, some users have already stockpiled supplies to avoid disruption.

The DEA’s move comes amidst ongoing efforts to regulate synthetic opioids, highlighting the continuous challenge of keeping pace with drug innovation and regulation.